Results 241 to 250 of about 69,036 (281)

Dopaminergic Degeneration Differentially Modulates Primary Motor Cortex Activity and Motor Behavior in Hemiparkinsonian Rats. [PDF]

Brain Sci
Boschen SL, Seethaler J, Wang S, Lujan WD, Silvernail JL, White LJ, Heckman MG, Carter RE, Chang SY, Lujan JL.   +9 more
europepmc   +1 more source

Acute Pharmacodynamic Effects of Oral Levodopa on Blood Pressure in Parkinson's Disease. [PDF]

Pharmacotherapy
Longardner K, Liu C, Momper J, Mahato K, Moonla C, Ghodsi H, Wang J, Litvan I.   +7 more
europepmc   +1 more source

Levodopa Added to Stroke Rehabilitation: The ESTREL Randomized Clinical Trial.

JAMA
Engelter ST, Kaufmann JE, Zietz A, Luft AR, Polymeris A, Altersberger VL, Wiesner K, Wiegert M, Held JPO, Rottenberger Y, Schwarz A, Medlin F, Accolla EA, Foucras S, Kägi G, De Marchis GM, Politz S, Greulich M, Tarnutzer AA, Sturzenegger R, Katan M, Fischer U, Nedeltchev K, Schär J, Van Den Keybus Deglon K, Rapin PA, Salerno A, Seiffge DJ, Auer E, Lippert J, Bonati LH, Schuster-Amft C, Gäumann S, Chabwine JN, Humm A, Möller JC, Schweinfurther R, Bujan B, Jedrysiak P, Sandor PS, Gonzenbach R, Mylius V, Lutz D, Lienert C, Peters N, Michel P, Müri RM, Schädelin S, Hemkens LG, Ford GA, Lyrer PA, Gensicke H, Traenka C, ESTREL Investigators.   +53 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Levodopa‐induced dyskinesias

Movement Disorders, 2007
AbstractLevodopa‐induced dyskinesias (LID) are common and difficult to treat. This review focuses on three issues related to LID: clinical features, classification and rating, pathophysiology and pathogenesis, and management. The three primary clinical syndromes are OFF‐period dystonia, peak‐dose dyskinesia, and diphasic dyskinesia. Several other forms
FABBRINI, Giovanni, Jonathan M. Brotchie, Francisco Grandas, Masahiro Nomoto, Christopher G. Goetz   +4 more
openaire   +3 more sources

Levodopa/levodopa/carbidopa

Reactions Weekly, 2023
  +4 more sources

Levodopa/levodopa/carbidopa

Reactions Weekly, 2022
openaire   +1 more source

Levodopa/levodopa/benserazide

Reactions Weekly, 2023
openaire   +1 more source

Levodopa/levodopa/benserazide

Reactions Weekly, 2022
openaire   +1 more source